Sunitinib Benefit Explored in Poor-Prognosis Kidney Cancer (HealthDay)

HealthDay - THURSDAY, July 16 (HealthDay News) — The oral cancer drug
sunitinib (Sutent) has shown promising results in advanced kidney cancer
patients who have a poor prognosis, new research says.

This entry was posted on Friday, July 17th, 2009 at 12:33 pm and is filed under Health. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.